A prominent policy expert positioned for a potential FDA leadership role faces mounting criticism from 'Make America Healthy Again' advocates who question his alignment with their health reform agenda. The controversy highlights internal tensions within the administration's health policy apparatus, as different factions compete to shape the nation's regulatory approach to pharmaceuticals and food safety during a pivotal period of healthcare transformation.

Summary auto-generated by AI from the original publisher's content. Editorial standards.